Masanori Taniwaki1, Maria D Radu1, Serge Zaugg1, Nicolas Amabile1, Hector M Garcia-Garcia1, Kyohei Yamaji1, Erik Jørgensen1, Henning Kelbæk1, Thomas Pilgrim1, Christophe Caussin1, Thomas Zanchin1, Aurelie Veugeois1, Ulrik Abildgaard1, Peter Jüni1, Stephane Cook1, Konstantinos C Koskinas1, Stephan Windecker1, Lorenz Räber2. 1. From Department of Cardiology, Bern University Hospital, Switzerland (M.T., K.Y., T.P., T.Z., K.C.K., S.W., L.R.); Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark (M.D.R., E..J.); Clinical Trials Unit, Bern University, Bern, Switzerland (S.Z.) Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael's Hospital, and Department of Medicine, University of Toronto, Canada (P.J.); Department of Cardiology, Institut Mutualiste Montsouris, Paris, France (N.A., C.C., A.V.); Interventional Cardilogy, Washington Hospital Center, Washington, DC (H.M.G.-G.); Department of Cardiology, Roskilde Hospital, Denmark (H.K.); Department of Cardiology, Copenhagen University Hospital Gentofte, Gentofte, Denmark (U.A.); and Department of Cardiology, Fribourg University and Hospital, Switzerland (S.C.). 2. From Department of Cardiology, Bern University Hospital, Switzerland (M.T., K.Y., T.P., T.Z., K.C.K., S.W., L.R.); Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark (M.D.R., E..J.); Clinical Trials Unit, Bern University, Bern, Switzerland (S.Z.) Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael's Hospital, and Department of Medicine, University of Toronto, Canada (P.J.); Department of Cardiology, Institut Mutualiste Montsouris, Paris, France (N.A., C.C., A.V.); Interventional Cardilogy, Washington Hospital Center, Washington, DC (H.M.G.-G.); Department of Cardiology, Roskilde Hospital, Denmark (H.K.); Department of Cardiology, Copenhagen University Hospital Gentofte, Gentofte, Denmark (U.A.); and Department of Cardiology, Fribourg University and Hospital, Switzerland (S.C.). lorenz.raeber@insel.ch.
Abstract
BACKGROUND: The pathomechanisms underlying very late stent thrombosis (VLST) after implantation of drug-eluting stents (DES) are incompletely understood. Using optical coherence tomography, we investigated potential causes of this adverse event. METHODS AND RESULTS: Between August 2010 and December 2014, 64 patients were investigated at the time point of VLST as part of an international optical coherence tomography registry. Optical coherence tomography pullbacks were performed after restoration of flow and analyzed at 0.4 mm. A total of 38 early- and 20 newer-generation drug-eluting stents were suitable for analysis. VLST occurred at a median of 4.7 years (interquartile range, 3.1-7.5 years). An underlying putative cause by optical coherence tomography was identified in 98% of cases. The most frequent findings were strut malapposition (34.5%), neoatherosclerosis (27.6%), uncovered struts (12.1%), and stent underexpansion (6.9%). Uncovered and malapposed struts were more frequent in thrombosed compared with nonthrombosed regions (ratio of percentages, 8.26; 95% confidence interval, 6.82-10.04; P<0.001 and 13.03; 95% confidence interval, 10.13-16.93; P<0.001, respectively). The maximal length of malapposed or uncovered struts (3.40 mm; 95% confidence interval, 2.55-4.25; versus 1.29 mm; 95% confidence interval, 0.81-1.77; P<0.001), but not the maximal or average axial malapposition distance, was greater in thrombosed compared with nonthrombosed segments. The associations of both uncovered and malapposed struts with thrombus were consistent among early- and newer-generation drug-eluting stents. CONCLUSIONS: The leading associated findings in VLST patients in descending order were malapposition, neoatherosclerosis, uncovered struts, and stent underexpansion without differences between patients treated with early- and new-generation drug-eluting stents. The longitudinal extension of malapposed and uncovered stent was the most important correlate of thrombus formation in VLST.
BACKGROUND: The pathomechanisms underlying very late stent thrombosis (VLST) after implantation of drug-eluting stents (DES) are incompletely understood. Using optical coherence tomography, we investigated potential causes of this adverse event. METHODS AND RESULTS: Between August 2010 and December 2014, 64 patients were investigated at the time point of VLST as part of an international optical coherence tomography registry. Optical coherence tomography pullbacks were performed after restoration of flow and analyzed at 0.4 mm. A total of 38 early- and 20 newer-generation drug-eluting stents were suitable for analysis. VLST occurred at a median of 4.7 years (interquartile range, 3.1-7.5 years). An underlying putative cause by optical coherence tomography was identified in 98% of cases. The most frequent findings were strut malapposition (34.5%), neoatherosclerosis (27.6%), uncovered struts (12.1%), and stent underexpansion (6.9%). Uncovered and malapposed struts were more frequent in thrombosed compared with nonthrombosed regions (ratio of percentages, 8.26; 95% confidence interval, 6.82-10.04; P<0.001 and 13.03; 95% confidence interval, 10.13-16.93; P<0.001, respectively). The maximal length of malapposed or uncovered struts (3.40 mm; 95% confidence interval, 2.55-4.25; versus 1.29 mm; 95% confidence interval, 0.81-1.77; P<0.001), but not the maximal or average axial malapposition distance, was greater in thrombosed compared with nonthrombosed segments. The associations of both uncovered and malapposed struts with thrombus were consistent among early- and newer-generation drug-eluting stents. CONCLUSIONS: The leading associated findings in VLST patients in descending order were malapposition, neoatherosclerosis, uncovered struts, and stent underexpansion without differences between patients treated with early- and new-generation drug-eluting stents. The longitudinal extension of malapposed and uncovered stent was the most important correlate of thrombus formation in VLST.
Authors: Florian Blachutzik; Niklas Boeder; Jens Wiebe; Alessio Mattesini; Oliver Dörr; Astrid Most; Timm Bauer; Jens Röther; Monique Tröbs; Christian Schlundt; Stephan Achenbach; Christian W Hamm; Holger M Nef Journal: Clin Res Cardiol Date: 2016-10-18 Impact factor: 5.460